Bispecific immunotherapy delivery system for lung diseases
Official title: Bispecific immunotherapeutic delivery system for lung diseases
Funded at Proteogenomics Research Instit/sys/ Med · NIH-11359649 · Data updated 2026-11-12
A new dual-precision delivery method is being developed to get immune therapies directly into the lungs to treat ARDS and related conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Proteogenomics Research Instit/sys/ Med NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | August 1, 2023 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $905,828 |
| NIH project number | 5R01HL169760-04 |
| Project ID | NIH-11359649 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with acute respiratory distress syndrome or other severe lung diseases where targeted lung delivery could be beneficial.
✕Less likely to help
Patients whose condition does not involve a lung-specific barrier or who cannot tolerate the proposed delivery method may derive little or no benefit.
What this research studies
This grant aims to design a targeted drug delivery system that uses a dual-precision approach to ferry immunotherapies into lung tissue after an IV dose. By focusing on lung-specific transcytosis through caveolae, the approach hopes to deliver more drug where it’s needed while reducing exposure elsewhere. If successful, it could lower required doses, reduce side effects, and improve outcomes for patients with acute respiratory distress syndrome and related lung diseases.
Why it matters
Potential benefit: If successful, patients with ARDS may experience more effective treatment with fewer side effects and lower treatment costs.
How similar studies have gone: Previous work shows that targeted delivery can improve tissue specificity, but this dual-precision lung-targeting approach is novel and unproven in humans.
Where this research is happening
-
Proteogenomics Research Instit/sys/ Med
La Jolla, United States Active
Researchers
- Principal investigator: Schnitzer, Jan Eugeniusz — Proteogenomics Research Instit/sys/ Med
- Study coordinator: Schnitzer, Jan Eugeniusz
Related research
Other NIH-funded projects on the same topics.
-
Clinical readiness for rare lung diseases (RLDC)
A group at the University of Cincinnati is building a program to speed up care for people with rare lung diseases by tracking patients over time, improving tests and treatments, and sharing information with patients and clinicians.
-
Epithelial cells trigger fibroblast activation in lung fibrosis through CTHRC1-TGFb signaling
A clinician-scientist at Duke is studying how lung lining cells may turn normal fibroblasts into fibrosis-causing cells, aiming to uncover new targets for treatment of diseases like BO and IPF.
-
Molecular origins of chronic lung diseases in the human lung
Researchers are mapping the tiny cell neighborhoods in diseased lungs to find early clues that could protect or restore normal lung function.
-
How lung cells and their surroundings drive fibrosis in interstitial lung diseases
A study to understand how airway cells, surrounding tissue, and their environment contribute to progressive scarring in interstitial lung diseases.
-
Loss of Cilia Maintenance in Acquired and Genetic Lung Diseases
Researchers are studying why tiny hair-like structures in the lungs lose their maintenance and how this affects people with asthma, COPD, and related airway diseases.
-
CMKLR1-targeted imaging to map lung inflammation in ALI and fibrotic lung diseases
A study to test a new PET imaging tool that targets CMKLR1 to visualize lung inflammation and help predict and monitor disease progression in patients with acute lung injury and fibrotic lung diseases.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.